Table 3.
Cardiovascular adverse events during and after carfilzomib treatment.
| Event | All Events | Severe Events, Severity Score ≥ 3 * |
|---|---|---|
| Arterial hypertension | 21 (30) | 4 (5.6) |
| - requiring intensification of antihypertensive therapy during carfilzomib treatment, n (%) | 17 (24.3) | 2 (2.8) |
| - requiring a temporary interruption in carfilzomib infusions, n (%) | 4 (5.7) | 2 (2.8) |
| Heart failure, n (%) | 0 (0) | 0 (0) |
| Myocardial infarction, n (%) | 1 (1.4) | 1 (1.4) |
| Chest pain, n (%) | 0 (0) | 0 (0) |
| Dyspnea, n (%) | 0 (0) | 0 (0) |
| Arrhythmias, n (%) | 1 (1.4) | 0 (0) |
| Valvular heart disease, n (%) | 0 (0) | 0 (0) |
| Pulmonary hypertension, n (%) | 0 (0) | 0 (0) |
| Thromboembolic events, n (%) | 0 (0) | 0 (0) |
| Cardiac arrest, n (%) | 0 (0) | 0 (0) |
| Total events, n (%) | 23 (32.9) | 5 (7.2) |
* Defined according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events).